

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/579,981	01/07/2007	Rocky Marc Cranenburgh	CARP-0123	3679
23377 7590 09/14/2007 WOODCOCK WASHBURN LLP		EXAMINER		
CIRA CENTRE, 12TH FLOOR			PITRAK, JENNIFER S	
2929 ARCH STREET PHILADELPHIA, PA 19104-2891			ART UNIT	PAPER NUMBER
			1635	
				•
			MAIL DATE	DELIVERY MODE
			09/14/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
Office Action Summany	10/579,981	CRANENBURGH, ROCKY MARC			
Office Action Summary	Examiner	Art Unit			
	Jennifer Pitrak	1635			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become AB ANDONE	J. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
1)⊠ Responsive to communication(s) filed on 04 Ja	nuary 2007				
	This action is FINAL . 2b)⊠ This action is non-final.				
· <u> </u>	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is				
·	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.				
Disposition of Claims	,,				
4)⊠ Claim(s) <u>1-41 and 44-73</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6) Claim(s) is/are rejected.					
7) Claim(s) is/are objected to.					
8)⊠ Claim(s) <u>1-41 and 44-73</u> are subject to restriction	on and/or election requirement.				
Application Papers					
9) The specification is objected to by the Examiner.					
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
12)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a)⊠ All b)□ Some * c)□ None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
3.⊠ Copies of the certified copies of the priority documents have been received in this National Stage					
application from the International Bureau (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a list of the certified copies not received.					
•					
Attachment(s)		·			
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)					
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	te			
Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	5) Notice of Informal P	atent Application			

Application/Control Number: 10/579,981

Art Unit: 1635

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-11, 13-37, and 41, drawn to a transformed host cell comprising a chromosomal gene which inhibits cell growth and a plasmid encoding an antisense sequence.

Group II, claim(s) 12, and 46-71, drawn to a host cell comprising a chromosomal gene which inhibits cell growth.

Group III, claim(s) 38-40, drawn to methods of maintaining a plasmid in a host cell *in vitro* and isolating plasmid DNA or protein from the cell.

Group IV, claim(s) 44, 72, and 73 drawn to methods of delivering a gene to a patient and immunizing a patient comprising administering a transformed host cell to the patient.

Group V, claim(s) 45, drawn to a method of maintaining a plasmid in a recipient organism.

The inventions listed as Groups I-V do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the special technical feature, an anti-sense sequence to a gene that inhibits cell growth, does not make a contribution over the prior art as anti-sense RNA to p53 is disclosed in Shohat, *et al.* (1987, Oncogene, v.1:227-283).

Art Unit: 1635

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

- A) prokaryotic or eukaryotic cell;
- B) gram negative or gram-positive bacteria;
- C) E. coli, Salmonella, or Bacillus;
- D) fungi, plant, or animal cell;
- E) the chromosomal genes encoding a toxin, a repressor protein, or an antisense sequence;
- F) lacI, dapD, or fabA.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The claims are deemed to correspond to the species listed above in the following manner:

Art Unit: 1635

A) prokaryotic or eukaryotic cell, claims 14, 21, 47, and 54;

- B) gram negative or gram-positive bacteria, claims 16, 18, 49, and 51;
- C) E. coli, Salmonella, or Bacillus, claims 17, 19, 50, and 52;
- D) fungi, plant, or animal cell, claims 22-24 and 55-57;
- E) the chromosomal genes encoding a toxin, a repressor protein, or an antisense sequence, claims 25, 27, 31, 58, 60, and 64;
- F) lacI, dapD, or fabA, claims 29, 30, 35, 62, and 68.

The following claim(s) are generic: claims 1 and 12.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: the species have mutually exclusive characteristics and are not obvious variants of each other based on the current record.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In

Application/Control Number: 10/579,981

Art Unit: 1635

either instance, if the examiner finds one of the inventions unpatentable over the prior art, the

evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Closing

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Jennifer Pitrak whose telephone number is 571-270-3061. The

examiner can normally be reached on Monday-Thursday, 7:30AM-5:00PM, ALT. Friday, EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, James Schultz can be reached on 571-272-0763. The fax phone number for the

organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would

like assistance from a USPTO Customer Service Representative or access to the automated

information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Jennifer Pitrak Patent Examiner AU 1635

Page 5